Quantcast

National Comprehensive Cancer Network Guidelines Available in Elekta’s MOSAIQ EMR

June 8, 2011

ATLANTA, June 8, 2011 /PRNewswire/ — Elekta has collaborated with the National Comprehensive Cancer Network® (NCCN®) to integrate the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines(TM)) into Elekta’s MOSAIQ® Oncology Information System. The collaboration offers Elekta users real-time access to NCCN’s evidence-based clinical content directly from within the MOSAIQ patient record.

The NCCN Guidelines are widely recognized as the standard for clinical policy in oncology in the United States and increasingly internationally,” says William T. McGivney, PhD, Chief Executive Officer, NCCN. “It is important that the NCCN Guidelines recommendations be available to clinicians in electronic decision-assist tools. The integration of NCCN Guidelines into MOSAIQ is a critical step in enhancing the evidentiary basis of clinical decision-making in oncology.”

The integration of the NCCN Guidelines in MOSAIQ eliminates the need for clinicians to change screens and login to separate systems, or to purchase the license separately. Now, from an open patient chart, MOSAIQ users simply right click to view the NCCN Guidelines pertaining to an individual patient’s cancer diagnosis. Easy access to the NCCN Guidelines results in real and measureable time-savings and faster, more informed decision making.

“This is just one more example of Elekta taking the leadership position in refining the capabilities of its electronic medical record (EMR) solution,” says Todd Powell, Executive Vice President, Elekta Software. “Most recently, MOSAIQ became the only oncology-specific, comprehensive EMR certified for Meaningful Use under the federal government’s HITECH Act. Now, with NCCN, we have significantly enhanced the ability for clinicians to use MOSAIQ as a clinical decision-making tool.”

The NCCN Guidelines are available now with MOSAIQ version 2.2 or above. To learn more, visit www.elekta.com/MOSAIQ.

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated state of the art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible.

Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. For more information about Elekta, please visit www.elekta.com.

SOURCE Elekta


Source: newswire



comments powered by Disqus